Pharmaceutical Commerce

Go in-between the pages and behind the scenes of Pharmaceutical Commerce Magazine

Episodes

Pharma Pulse: Novartis Buys Avidity for $12B, and Trump Threatens 10% Tariff Hike on Canada

October 28, 2025 • 2 mins

This episode of Pharma Pulse discusses Novartis’ $12 billion acquisition of Avidity Biosciences to expand its RNA therapeutics portfolio, and Trump’s proposed 10% tariff increase on Canadian imports that could disrupt pharma supply chains.

Mark as Played

Pharma Pulse: Cholesterol Imbalance Tied to Depression Risk, Lilly Acquires Aderum Biotechnologies, and Cambrex Expands API Manufacturing

October 27, 2025 • 2 mins

This episode of Pharma Pulse discusses new research linking cholesterol imbalance in obesity to higher depression risk, Eli Lilly’s acquisition of Aderum Biotechnologies to strengthen its neuroscience pipeline, and Cambrex’s $120 million investment to boost US API manufacturing capacity.

Mark as Played

Pharma Pulse: Alkermes Acquires Avadel in $2.1B Deal, BioNTech Moves to Buy CureVac, and MedTech Industry Embraces Digital-First Models

October 24, 2025 • 2 mins

This episode of Pharma Pulse covers Alkermes’ acquisition of Avadel Pharmaceuticals to expand its portfolio, BioNTech’s public exchange offer for CureVac to strengthen its mRNA pipeline, and a new report revealing how US medical device manufacturers are adopting digital-first models to boost compliance and patient engagement.

Mark as Played

Pharma Pulse: MJH Life Sciences Expands into Health Systems, Novo Nordisk Board Shakeup Moves Markets, and Mark Cuban Grows Cost Plus Drugs Network

October 23, 2025 • 2 mins

This episode of Pharma Pulse covers MJH Life Sciences’ acquisition of BPD Healthcare to deepen its reach into hospitals and health systems, investor reaction to Novo Nordisk’s recent board changes, and Mark Cuban’s latest partnership expanding his Cost Plus Drugs platform to disrupt traditional pharmacy pricing models.

Mark as Played

Pharma Pulse: Telehealth Medication Abortion Requests Surge, FDA Expedites Tzield Review, and New Biopharma Air Network Launches

October 22, 2025 • 2 mins

This episode of Pharma Pulse discusses new data showing a post-Dobbs surge in telehealth medication abortion requests, the FDA’s expedited review of Tzield under its new National Priority Voucher Program, and the launch of a dedicated biopharma air logistics network by Frontier Scientific Solutions and ATSG.

Mark as Played

Pharma Pulse: Amazon Enters Weight-Loss Drug Market, Merck Expands US Manufacturing, and FDA Approves Tezspire for Chronic Sinusitis

October 21, 2025 • 2 mins

This episode of Pharma Pulse covers Amazon and WeightWatchers’ partnership to deliver FDA-approved weight-loss medications, Merck’s new biomanufacturing center of excellence in Virginia, and the FDA’s first-ever approval of a TSLP-targeting biologic, Tezspire, for chronic rhinosinusitis with nasal polyps.

Mark as Played

Pharma Pulse: Severe COVID-19 Raises Stroke Risk in Asthma Patients, Parents Divided on Vaccine Policies, and 2026 Medicare Rankings Revealed

October 20, 2025 • 2 mins

This episode of Pharma Pulse discusses new research linking severe COVID-19 to increased stroke risk among asthma patients, a KFF poll showing divided parental support for vaccine-related agendas, and US News & World Report’s 2026 list of top Medicare Advantage and Part D plan providers.

Mark as Played

Pharma Pulse: Cancer Care Gaps Persist, Physician Pay Hits Record Highs, and AstraZeneca Expands Texas Manufacturing

October 17, 2025 • 2 mins

This episode of Pharma Pulse discusses new research revealing persistent disparities in women’s cancer outcomes, record-high physician pay amid steady productivity, and AstraZeneca’s major Texas expansion to double production of its hyperkalemia treatment, Lokelma.

Mark as Played

Pharma Pulse: FDA Approves One-Minute HIV Test, US Delays Pharma Tariffs, and CVS Acquires 600 Rite Aid Stores

October 16, 2025 • 2 mins

This episode of Pharma Pulse covers the FDA’s approval of a rapid one-minute HIV self-test, the US government’s decision to delay tariffs on pharmaceutical exports from Singapore, and CVS Pharmacy’s acquisition of more than 600 Rite Aid stores across three states to expand its community health footprint.

Mark as Played

Pharma Pulse: Kaiser Permanente Strike Escalates, Takeda Partners with Nabla Bio, and FDA Flags Novo Nordisk Bloomington Site

October 15, 2025 • 2 mins

This episode of Pharma Pulse covers the nationwide Kaiser Permanente strike involving more than 40,000 healthcare workers, Takeda’s new AI-driven antibody discovery partnership with Nabla Bio, and the FDA’s OAI designation for Novo Nordisk’s Bloomington manufacturing facility.

Mark as Played

Pharma Pulse: CDC Layoffs Raise Public Health Concerns as Ypsomed and Lupin Expand US Manufacturing Footprint

October 14, 2025 • 2 mins

This episode of Pharma Pulse covers how recent CDC layoffs are fueling concerns about disease surveillance, Ypsomed’s new autoinjector manufacturing site in North Carolina, and Lupin’s $250 million investment to build a respiratory and specialty drug facility in Florida.

Mark as Played

Pharma Pulse: Mark Cuban Disrupts Drug Pricing, AstraZeneca Expands US Manufacturing, and BMS Bets Big on RNA Therapeutics

October 13, 2025 • 2 mins

This episode of Pharma Pulse covers how Mark Cuban’s direct-to-consumer pharmacy is challenging traditional drug pricing models, AstraZeneca’s $4.5 billion investment to expand its Virginia manufacturing site, and Bristol Myers Squibb’s $1.5 billion acquisition of Orbital Therapeutics to advance RNA-based medicines.

Mark as Played

Pharma Pulse: CDC Updates Vaccine Guidance, GLP-1s Linked to Imaging Challenges, and Novo Nordisk Loses Inflation Reduction Act Appeal

October 10, 2025 • 2 mins

This episode of Pharma Pulse covers the CDC’s new individualized approach to COVID-19 vaccination and changes to chickenpox guidance for toddlers, new research showing how GLP-1 therapies can interfere with PET-CT imaging results, and the Third Circuit Court’s rejection of Novo Nordisk’s IRA challenge.

Mark as Played

Pharma Pulse: FDA Expands Pediatric UC Treatment Options, AstraZeneca and Algen Partner in Neurology, and Peli BioThermal Boosts Cold Chain Capabilities

October 9, 2025 • 2 mins

This episode of Pharma Pulse covers the FDA’s approval of golimumab for pediatric ulcerative colitis, AstraZeneca’s new multi-target neuroscience partnership with Algen, and Peli BioThermal’s acquisition of Evo to strengthen its global cold chain portfolio.

Mark as Played

Pharma Pulse: Study Links Early Obesity to Postpartum Diabetes Risk, Amgen Launches AmgenNow, and Eli Lilly Strengthens Global Supply Chain

October 8, 2025 • 2 mins

This episode of Pharma Pulse covers new research showing how obesity at age 20 increases postpartum diabetes risk, Amgen’s new direct-to-consumer digital platform aimed at improving treatment access, and Eli Lilly’s $1 billion investment to strengthen manufacturing in India.

Mark as Played

Pharma Pulse: NIAID Whistleblower Controversy, ALS Linked to Autoimmunity, and Hospital Layoffs Accelerate Nationwide

October 7, 2025 • 2 mins

This episode of Pharma Pulse covers allegations of retaliation against a former NIAID director following whistleblower complaints, new research suggesting ALS may be an autoimmune disease, and the wave of hospital layoffs affecting thousands of healthcare workers across the United States.

Mark as Played

Pharma Pulse: FDA Approves First Generic Mifepristone, Takeda Exits Cell Therapy Research, and SciSafe Expands Biopharma Storage

October 6, 2025 • 2 mins

This episode of Pharma Pulse covers the FDA’s quiet approval of the first generic mifepristone tablet, Takeda’s decision to discontinue cell therapy research programs, and SciSafe’s expansion of biopharma storage capacity with a new East Brunswick, New Jersey facility.

Mark as Played

Pharma Pulse: FDA Faces Shutdown Risks, Aetna Unveils 2026 Medicare Advantage Plans, and US Maternal Mortality Remains High

October 3, 2025 • 2 mins

This episode of Pharma Pulse covers the potential ramifications of a federal government shutdown on FDA operations, Aetna’s newly announced 2026 Medicare Advantage offerings, and new research showing maternal and child mortality rates in the US remain higher than in most high-income nations.

Mark as Played

Pharma Pulse: Telehealth Access at Risk During Shutdown, Medicare Advantage SNPs Surge, and Halozyme Buys Elektrofi for $750M

October 2, 2025 • 2 mins

This episode of Pharma Pulse covers ATA’s warning that telehealth protections are critical to maintaining care access during a potential federal shutdown, new KFF data showing the rapid rise of Medicare Advantage special needs plans, and Halozyme’s $750 million acquisition of Elektrofi to expand its drug delivery portfolio.

Mark as Played

Pharma Pulse: Trump Plans Direct-to-Patient Website, Gabapentin Prescriptions Surge, and Gene Therapy Slows Huntington’s Progression

October 1, 2025 • 2 mins

This episode of Pharma Pulse covers the Trump administration’s plan to launch a government-run healthcare website for patients, new data showing gabapentin has become the fifth most prescribed drug in community pharmacies, and promising trial results from a novel gene therapy that slows the progression of Huntington’s disease.

Mark as Played

Popular Podcasts

On Purpose with Jay Shetty

I’m Jay Shetty host of On Purpose the worlds #1 Mental Health podcast and I’m so grateful you found us. I started this podcast 5 years ago to invite you into conversations and workshops that are designed to help make you happier, healthier and more healed. I believe that when you (yes you) feel seen, heard and understood you’re able to deal with relationship struggles, work challenges and life’s ups and downs with more ease and grace. I interview experts, celebrities, thought leaders and athletes so that we can grow our mindset, build better habits and uncover a side of them we’ve never seen before. New episodes every Monday and Friday. Your support means the world to me and I don’t take it for granted — click the follow button and leave a review to help us spread the love with On Purpose. I can’t wait for you to listen to your first or 500th episode!

The Joe Rogan Experience

The official podcast of comedian Joe Rogan.

Stuff You Should Know

If you've ever wanted to know about champagne, satanism, the Stonewall Uprising, chaos theory, LSD, El Nino, true crime and Rosa Parks, then look no further. Josh and Chuck have you covered.

The Clay Travis and Buck Sexton Show

The Clay Travis and Buck Sexton Show. Clay Travis and Buck Sexton tackle the biggest stories in news, politics and current events with intelligence and humor. From the border crisis, to the madness of cancel culture and far-left missteps, Clay and Buck guide listeners through the latest headlines and hot topics with fun and entertaining conversations and opinions.

Dateline NBC

Current and classic episodes, featuring compelling true-crime mysteries, powerful documentaries and in-depth investigations. Follow now to get the latest episodes of Dateline NBC completely free, or subscribe to Dateline Premium for ad-free listening and exclusive bonus content: DatelinePremium.com

Advertise With Us

Pharmaceutical Commerce

Episodes

.css-14f5ked{margin:0;word-break:break-word;display:-webkit-box;-webkit-box-orient:vertical;box-orient:vertical;-webkit-line-clamp:2;overflow:hidden;}Pharma Pulse: Novartis Buys Avidity for $12B, and Trump Threatens 10% Tariff Hike on Canada

.css-r6mb8g{margin:0;word-break:break-word;display:-webkit-box;-webkit-box-orient:vertical;box-orient:vertical;-webkit-line-clamp:1;overflow:hidden;}Pharma Pulse: Cholesterol Imbalance Tied to Depression Risk, Lilly Acquires Aderum Biotechnologies, and Cambrex Expands API Manufacturing

Pharma Pulse: Alkermes Acquires Avadel in $2.1B Deal, BioNTech Moves to Buy CureVac, and MedTech Industry Embraces Digital-First Models

Pharma Pulse: MJH Life Sciences Expands into Health Systems, Novo Nordisk Board Shakeup Moves Markets, and Mark Cuban Grows Cost Plus Drugs Network

Pharma Pulse: Telehealth Medication Abortion Requests Surge, FDA Expedites Tzield Review, and New Biopharma Air Network Launches

Pharma Pulse: Amazon Enters Weight-Loss Drug Market, Merck Expands US Manufacturing, and FDA Approves Tezspire for Chronic Sinusitis

Pharma Pulse: Severe COVID-19 Raises Stroke Risk in Asthma Patients, Parents Divided on Vaccine Policies, and 2026 Medicare Rankings Revealed

Pharma Pulse: Cancer Care Gaps Persist, Physician Pay Hits Record Highs, and AstraZeneca Expands Texas Manufacturing

Pharma Pulse: FDA Approves One-Minute HIV Test, US Delays Pharma Tariffs, and CVS Acquires 600 Rite Aid Stores

Pharma Pulse: Kaiser Permanente Strike Escalates, Takeda Partners with Nabla Bio, and FDA Flags Novo Nordisk Bloomington Site

Pharma Pulse: CDC Layoffs Raise Public Health Concerns as Ypsomed and Lupin Expand US Manufacturing Footprint

Pharma Pulse: Mark Cuban Disrupts Drug Pricing, AstraZeneca Expands US Manufacturing, and BMS Bets Big on RNA Therapeutics

Pharma Pulse: CDC Updates Vaccine Guidance, GLP-1s Linked to Imaging Challenges, and Novo Nordisk Loses Inflation Reduction Act Appeal

Pharma Pulse: FDA Expands Pediatric UC Treatment Options, AstraZeneca and Algen Partner in Neurology, and Peli BioThermal Boosts Cold Chain Capabilities

Pharma Pulse: Study Links Early Obesity to Postpartum Diabetes Risk, Amgen Launches AmgenNow, and Eli Lilly Strengthens Global Supply Chain

Pharma Pulse: NIAID Whistleblower Controversy, ALS Linked to Autoimmunity, and Hospital Layoffs Accelerate Nationwide

Pharma Pulse: FDA Approves First Generic Mifepristone, Takeda Exits Cell Therapy Research, and SciSafe Expands Biopharma Storage

Pharma Pulse: FDA Faces Shutdown Risks, Aetna Unveils 2026 Medicare Advantage Plans, and US Maternal Mortality Remains High

Pharma Pulse: Telehealth Access at Risk During Shutdown, Medicare Advantage SNPs Surge, and Halozyme Buys Elektrofi for $750M

Pharma Pulse: Trump Plans Direct-to-Patient Website, Gabapentin Prescriptions Surge, and Gene Therapy Slows Huntington’s Progression

Popular Podcasts

Pharma Pulse: Novartis Buys Avidity for $12B, and Trump Threatens 10% Tariff Hike on Canada

Pharma Pulse: Cholesterol Imbalance Tied to Depression Risk, Lilly Acquires Aderum Biotechnologies, and Cambrex Expands API Manufacturing